Today: 20 March 2026
Subscribe
Browse Category

Pfizer News 4 November 2025 - 2 December 2025

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer shares rose 1.7% to $25.65 by early afternoon Tuesday after the company completed a $10 billion acquisition of obesity-drug developer Metsera. The stock traded between $25.24 and $25.96, with a market cap near $143 billion. Pfizer also reported new FDA approval for PADCEV plus Keytruda in bladder cancer and continued strong options activity at the $25 strike.
25 November 2025
···
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer and Tris Pharma agreed to pay $41.5 million to settle Texas claims over adulterated ADHD drug Quillivant XR. Pfizer also announced a research deal with Nona Biosciences for antibody discovery. At the Jefferies Healthcare Conference, management reaffirmed $7.7 billion in cost cuts and a push into obesity drugs. PFE traded near $25.37 early Wednesday, slightly down from the prior close.
19 November 2025
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock Today, November 12, 2025: Shares Nudge Higher as Jefferies Webcast Set, Metsera Deal Stays in Focus

Pfizer shares rose 1.7% to $25.94 Wednesday afternoon, trading in a narrow range ahead of next week’s CFO webcast at the Jefferies London Healthcare Conference. Investors are watching for updates on Pfizer’s $10 billion Metsera obesity-drug deal, with a shareholder vote set for November 13. Pfizer recently raised its 2025 EPS outlook and declared a $0.43 Q4 dividend. Market sentiment improved after positive media commentary.
12 November 2025
···
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Pfizer shares fell 2.3% to $24.28 amid heavy trading as a Delaware judge allowed Metsera to exit its deal with Pfizer, intensifying the takeover battle with Novo Nordisk. Pfizer is reportedly considering a higher bid ahead of Metsera’s Nov. 13 shareholder vote. The company marked its dividend record date today for a $0.43 payout. Earlier this week, Pfizer raised its 2025 EPS guidance after beating Q3 estimates.
7 November 2025
····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer shares traded near $24.60 on Nov. 4, 2025, down about 8–9% year-to-date and over 60% from their 2021 peak. Q3 adjusted earnings beat forecasts at $0.87 per share, but revenue missed slightly at $16.65 billion. Pfizer raised its full-year profit outlook and reaffirmed revenue guidance. The company is locked in a takeover battle with Novo Nordisk for obesity drug developer Metsera.
4 November 2025
·····
1 2

Stock Market Today

  • Robert Half (RHI) Stock Faces Steep Decline but Shows Potential Value Gap
    March 20, 2026, 6:13 AM EDT. Robert Half (RHI) shares dropped about 7% over one month and roughly 18% over three months, with a sharp 54% decline over one year, highlighting fading momentum. The stock's latest price at $22.95 trails the fair value estimate of $32.39, suggesting a roughly 29% undervaluation according to analyst narratives. Growth drivers include rising demand for flexible workforce staffing, enhanced consulting services amid regulatory challenges, and margin expansion prospects. However, recent revenue softness and increased selling, general and administrative (SG&A) costs pose risks to profitability. Investors should weigh the company's growth potential against headwinds amid mixed market sentiment. Broader diversification and careful scrutiny of evolving fundamentals are advised amid Robert Half's recent performance shifts.
Go toTop